OncoMatch/Clinical Trials/NCT00107289
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Is NCT00107289 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies iobenguane I 131 for neuroblastoma.
Treatment: iobenguane I 131 — The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroblastoma
Disease stage
Required: Stage PROGRESSIVE, REFRACTORY
history of tumor progression or recurrence or failure to achieve complete response with standard therapy; evaluable disease on MIBG scan
Demographics
Lab requirements
Kidney function
grade 2 or less renal toxicity
Liver function
grade 2 or less hepatic toxicity
Cardiac function
grade 2 or less cardiac toxicity
renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less. A grade 3 hearing deficit is acceptable.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT00107289 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage PROGRESSIVE or REFRACTORY is required.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages